Supplementary Figure 4 from Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy
Year: 2023
Type: supplementary-materials
Abstract: PDF file - 62KB, Kaplan-Meier PFS according to level of expression of hsa-miR-31-3p in the whole series of 132 patients. For the 102 patients who were NRAS wild-type based on Sanger sequencing of exon 2 and 3, the hazard ratio was 2.51 CI95 percent (1.6-4) and the median progression free survival was 10.14 and 35.71 weeks respectively for the high and low risk groups.
Authors: Gilles Manceau, Sandrine Imbeaud, Raphaële Thiébaut, François Liébaert, Karine Fontaine, Francis Rousseau, Bérengère Génin, Delphine Le Corre, Audrey Didelot, Marc Vincent, Jean-Baptiste Bachet, Benoist Chibaudel, Olivier Bouché, Bruno Landi, Frédéric Bibeau, Karen Leroy, Frédérique Penault-Llorca, Jean-Luc Van Laethem, Pieter Demetter, Sabine Tejpar, Simona Rossi, Neda Mosakhani, Pia Österlund, Raija Ristamäki, Virinder Sarhadi, Sakari Knuutila, Valérie Boige, Thierry André, Pierre Laurent-Puig
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361908354